Canada Life
PBE icon

Canada Life’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Canada Life’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-2,000
Closed -$101K – 2580
2014
Q4 		$101K Hold
2,000
– – ﹤0.01% 1746
2014
Q3 		$81K Hold
2,000
– – ﹤0.01% 1837
2014
Q2 		$77K Buy
+2,000
New +$81K ﹤0.01% 1737

Other funds holding PBE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
TAM
Trillium Asset Management Boston, Massachusetts $3.01B AUM 19.96% 1-Year Est. Return
QA
Quantitative Advantage Minnetonka, Minnesota $689M AUM 6.25% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $1.7B AUM 39.15% 1-Year Est. Return

Canada Life's PBE Position: Q1 2015 in Review

Canada Life sold out of Invesco Biotechnology & Genome ETF (PBE) in Q1 2015, closing a stake of 2,000 shares — an estimated $101K sold.

Canada Life first reported a position in PBE in Q2 2014 and held it in 3 quarters. The position peaked at $101K in Q4 2014. 87 funds tracked by Wall St. Rank hold PBE as of Q1 2015.

  • Canada Life reported no remaining Invesco Biotechnology & Genome ETF position as of Q1 2015 after selling out during the quarter.
  • Canada Life sold 2,000 Invesco Biotechnology & Genome ETF shares in Q1 2015, an estimated $101K.
  • Canada Life first reported a position in Invesco Biotechnology & Genome ETF in Q2 2014 and held it in 3 quarters.
  • Canada Life's Invesco Biotechnology & Genome ETF position peaked at $101K in Q4 2014.
  • 87 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2015.

Based on Canada Life's 13F filing for Q1 2015, filed 6 May 2015.